The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, fueled by rising cancer cases and advances in precision oncology such as next-generation sequencing and AI diagnostics. Biomarkers help tailor treatments to individual patients, improving outcomes in targeted therapies and immuno-oncology. North America leads the market due to strong healthcare infrastructure and investment, while challenges include high R&D costs and regulatory hurdles. Growth is expected across multiple cancer types, with breast cancer biomarker testing holding the largest market share.
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
ResearchAndMarkets.com released a comprehensive report analyzing over 1,230 bioinformatics collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, including upfront payments, milestones, royaltie...
